<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373879</url>
  </required_header>
  <id_info>
    <org_study_id>VAC041</org_study_id>
    <nct_id>NCT01373879</nct_id>
  </id_info>
  <brief_title>AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic Area</brief_title>
  <official_title>Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults and Children in a Malaria Endemic Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the safety and immunogenicity of MVA ME-TRAP and
      AdCH63 ME-TRAP candidate vaccines in healthy children and adult volunteers in a malaria
      endemic region. The regimen proposed here has protected non-immune volunteers in Oxford
      against sporozoite challenge, and so may be protective against naturally acquired infection
      in The Gambia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of a heterologous prime-boost vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP</measure>
    <time_frame>Participants will be followed for the duration of the study, an expected average of 12 months</time_frame>
    <description>To assess the safety of a heterologous prime-boost vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in healthy adults and children in The Gambia by recording local and systemic solicited and unsolicited adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of a heterologous prime-boost vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP</measure>
    <time_frame>Participants will be followed for the duration of the study, an expected average of 12 months</time_frame>
    <description>To assess the immunogenicity of a heterologous prime-boost vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in healthy adults and children in The Gambia by assessing induced antibody and T cell response to the vaccine insert.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME TRAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children (2-6 years old) vaccinated with human diploid cell rabies vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children (2-6 years old) vaccinated with human diploid cell rabies vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 ME-TRAP, MVA ME-TRAP</intervention_name>
    <description>AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later</description>
    <arm_group_label>Group 1A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 ME-TRAP, MVA ME-TRAP</intervention_name>
    <description>AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later</description>
    <arm_group_label>Group 1B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 ME-TRAP, MVA ME-TRAP</intervention_name>
    <description>AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later</description>
    <arm_group_label>Group 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 ME-TRAP, MVA ME-TRAP</intervention_name>
    <description>AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later</description>
    <arm_group_label>Group 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HDCRV</intervention_name>
    <description>HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later</description>
    <arm_group_label>Group 2C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 ME-TRAP, MVA ME-TRAP</intervention_name>
    <description>AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later</description>
    <arm_group_label>Group 3A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 ME-TRAP, MVA ME-TRAP</intervention_name>
    <description>AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later</description>
    <arm_group_label>Group 3B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HDCRV</intervention_name>
    <description>HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later</description>
    <arm_group_label>Group 3C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consenting adult males aged 18-50 years in good health and healthy children aged 2-6
             years.with consenting parents.

        Exclusion Criteria:

          -  Clinically significant history of skin disorder (psoriasis, contact dermatitis etc.),
             allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease,
             endocrine disorder, liver disease, renal disease, gastrointestinal disease,
             neurological illness.

          -  Severe malnutrition.

          -  Hypersensitivity to HDCRV.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines, e.g. egg products, Kathon, neomycin, betapropiolactone.

          -  History of splenectomy Haemoglobin less than 9.0 g/dL, where judged to be clinically
             significant in the opinion of the investigator

          -  Serum Creatinine concentration greater than 70 mol/L, where judged to be clinically
             significant in the opinion of the investigator

          -  Serum ALT concentration greater than 45 U/L, where judged to be clinically significant
             in the opinion of the investigator

          -  Blood transfusion within one month of enrolment.

          -  History of vaccination with previous experimental malaria vaccines.

          -  Administration of any other vaccine or immunoglobulin within two weeks before
             vaccination.

          -  Current participation in another clinical trial, or within 12 weeks of this study.

          -  Any other finding which in the opinion of the investigators would increase the risk of
             an adverse outcome from participation in the trial.

          -  Likelihood of travel away from the study area.

          -  HIV positive.

          -  Positive malaria antigen test
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kalifa Bojang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research Council PO Box 273, Banjul The Gambia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Kalifa Bojang</name>
      <address>
        <city>Banjul</city>
        <country>Gambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gambia</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

